Arylesterase. Methodological and functional aspects of a key enzyme in the cardiovascular disease. Part I;Arilesterasa. Aspectos metodológicos y funcionales de una enzima clave en la enfermedad cardiovascular. Parte I

Anales de la Real Academia Nacional de Farmacia

Volumn 74, Issue 1, 2008, Pages 5-27

  Nus, Meritxell ^a   Sánchez Muniz, Francisco J ^a   Sánchez Montero, José M ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Arylesterase; Atherosclerosis; Human serum mimetic; Oxidized LDL; Polymorphisms

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; BUFFER; CHOLESTEROL; GLUCONOLACTONASE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ACCURACY; ATHEROSCLEROSIS; CALORIMETRY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIET; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME POLYMORPHISM; ENZYME SUBSTRATE COMPLEX; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; METHODOLOGY; MORTALITY; NONHUMAN; REPRODUCIBILITY; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETRY;

EID: 49149114253     PISSN: None     EISSN: 1697428X     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. LEAL, J.; LUENGO-FERNÁNDEZ, R.; GRAY, A.; PETERSEN, S., RAYNER, M. (2006): Economic burden of cardiovascular diseases in the enlarged European Union. Eur. Heart J. 27: 1610-1619.
2. INSTITUTO NACIONAL DE ESTADÍSTICA (2002): Defunciones según causa de muerte. www.ine.es
3. GOLDSTEIN, J. L. and BROWN, M. S. (1977): The low-density lipoprotein pathway and its relation to atherosclerosis. Ann. Rev. Biochem. 46: 897-930.
4. ROSS, R. (1999): Atherosclerosis an inflammatory disease. N. Eng. J. Med. 340: 115.
5. STEINBERG, D.; PARTHASARATHY, S. and CAREW, T. E. (1989): Beyond cholesterol: Modifications of low density lipoproteins that increase its atherogenicity. N. Eng. J. Med. 320: 915-924.
6. SÁNCHEZ-MUNIZ, F. J.; VARELA, P.; BASTIDA, S. and GONZALEZ, J. M. (2001): Enfermedad cardiovascular, hipertensión arterial y dislipemias, en Cuidados farmacológicos y nutricionales en el paciente en la edad avanzada (Carvajal, A.; Varela, P. Eds.).
7. MESA, M. D.; AGUILERA, C. M.; RAMÍREZ- TORTOSA, C. L.; GIL, A. and RAMÍREZ- TORTOSA, M. C. (2006): Effect of olive oil on cardiovascular risk factor, LDL oxidation and atherosclerosis development, en Olive Oil and Health (Quiles, J. L.; Ramírez-Tortosa, M. C.; Yaqoob, P. Eds.), pp. 194-222. Cabi, Oxfordshire, UK.
8. SÁNCHEZ-MUNIZ, F. J. and SÁ NCHEZ-MONTERO, J. M. (1999): Enzymatic methods for the study of thermally oxidized oils and fats, en Frying of Food. Oxidation, Nutrient and Non-Nutrient antioxidants, Biologically Active Compounds and High Temperatures (Boskou, D.; Elmadfa, I. Eds.), pp. 105-142, Technomic Publishing Co. Lancaster, USA.
9. ASZTALOS, B. F.; ROHEIM, P. S.; MILANI, R. L.; LEFEVRE, M.; MCNAMARA, J. R.; HORVATH, K. V. and SCHAEFER, E. J. (2000): Distribution of Apo A-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 20: 2670-2676.
10. BARTER, P. J. (2002): Hugh Sinclair Lecture: The regulation and remodelling of HDL by plasma factors. Atherosclerosis Suppl. 3: 39-47.
11. NAVAB, M.; BERLINER, J. A.; SUBBANAGOUNDER, G. and HAMA, S. Y. (2001): HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 21: 481-488.
12. NAVAB, M.; BERLINER, J. A.; WATSON, A. D.; HAMA, S. Y.; TERRITO, M. C.; LUSIS, A. J., et al. (1996): The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vasc. Biol. 16: 831-842.
13. MINNA, L.; HANNUKSELA, M. E.; BROUSSEAU, S. M.; MEYN, H. N.; GIOVANNI BADER, R. D.; SHAMBUREK, P. A. and BREWER, H. B. JR. (2002): In vivo metabolism of apolipoprotein E within the HDL subpopulations LpE, LpE:A-I, LpE:A-II and LpE:A-I:A-II. Atherosclerosis. 165: 205-220.
14. BERGMEIER, C.; SIEKMEIER, R. and GROSS, W. (2004): Distribution spectrum of paraoxonase activity in HDL fractions. Clin. Chem. 50: 2309-2315.
15. CANALES, A. and SÁNCHEZ-MUNIZ, F. J. (2003): La paraoxonasa, ¿algo más que un enzima? Med. Clin. (Barc.). 121: 537-548.
16. HAREL, M.; AHARONI, A.; GAIDUKOV, L.; BRUMSHTEIN, B.; KHERSONSKY, O.; MEGED, R.; DVIR, H.; RAVELLI, R. B. G.; MCCARTHY, A.; TOKER L., et al. (2004): Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 11: 412-419.
17. PROTEIN DATA BANK http://www.rcsb.org/pdb/ navbarsearch.do?newSearch=yes&isAuthorSearch=no&radioset= All&inputQuickSearch=1v04.
18. KUO, C. L. and LA DU, B. N. (1998): Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. Drug Metab. Disp. 26: 653-660.
19. YEUNG, D. T.; LENZ, D. E. and CERASOLI, D. M. (2005): Analysis of active-site amino-acid residues of human serum paraoxonase using competitive substrates. FEBS J. 272: 2225-2230.
20. SÁNCHEZ-MONTERO, J. M. and NUS, M.: Observaciones sin publicar.
21. AVIRAM, M.; ROSENBLAT, M.; BILLECKE, S.; EROGUL, J.; SORENSON, R.; BISGAIER, C. L.; NEWTON, R. S. and LA DU, B. (1999): Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Rad. Biol. Med. 26: 892-904.
22. AVIRAM, M.; ROSENBLAT, M.; BISGAIER, C. L.; NEWTON, R. S.; PRIMO-PARMO, S. L. and LA DU, B. N. (1998): Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions, a possible peroxidative role for para-oxonase. J. Clin. Invest. 101: 1581-1590.
23. MACKNESS, B.; HINE, D.; LIU, Y.; MASTORIKOU, M. and MACKNESS, M. (2004): Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem. Biophys. Res. Commun. 318: 680-683.
24. FUHRMAN, B.; VOLKOVA, N. and AVIRAM, M. (2002): Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized LDL in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase. Atherosclerosis. 161: 307-316.
25. ROZENBERG, O.; SHIH, D. M. and AVIRAM, M. (2003): Human serum paraoxonase (PON1) decreases macrophage cholesterol biosynthesis: a possible role for its phospholipase-A2 activity and lysophosphatidylcholine formation. Arterioscler. Thromb. Vasc. Biol. 23: 461-467.
26. ROSENBLAT, M.; VAYA, J.; SHIH, D. M. and AVIRAM, M. (2005): Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcoline. Atherosclerosis. 179: 69-77.
27. MACKNESS, B.; DURRINGTON, P. N.; MCELDUFF, P., et al. (2003): Low paraoxonase activity predicts coronary events in the Caerphilly prospective. Circulation. 107: 2775-2779.
28. TOMÁS, M.; SENTÍ, M.; GARCÍA-FARIA, F.; VILA, J.; TORRENTS, A.; COVAS, M. and MARRUGAT, J. (2000): Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 20: 2113-2119.
29. ABBOTT, C. A.; MACKNESS, M. I.; KUMAR, S., et al. (1995): Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15: 1812-1818.
30. SUTHERLAND, W. H. F.; MANNING, P. J.; DE JONG, S. A.; ALLUM, A. R.; JONES, S. D. and WILLIAMS, S. M. (2001): Hormone-replacement therapy increases serum paraoxonase/arylesterase activity in diabetic postmenopausal women. Metabolism. 50: 319-324.
31. FERRÉ, N.; CAMPS, J.; PRATS, E.; VILELLA, E.; PAUL, A.; FIGUERA, L. and JOVEN, J. (2002): Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin. Chem. 48: 261-268.
32. SUTHERLAND, W. H. F.; DE JONG, S. A. and WALKER, R. J. (2004): Hypochlorous acid and low serum paraoxonase activity in haemodialysis patients: an in vitro study. Nephrol. Dial. Transplant. 19: 75-82.
33. SARANDOL, E.; SERDAR, Z.; DIRICAN, M. and SAVAK, O. (2003): Effects of red wine consumption on serum paraoxonase/arylesterasa activities and on lipoprotein oxidizability in healthy-men. J. Nutr. Biochem. 14: 507-512.
34. WALLACE, A. J.; SUTHERLAND, W. H. F.; MANN, J. I. and WILLIAMS; S. M. (2001): The effect of meals rich in thermally stressed olive and safflower oils on postprandial serum paraoxonase activity in patients with diabetes. Eur. J. Clin. Nutr. 55: 951-958.
35. LEVIEV, I. and JAMES, R. W. (2000): Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20: 516-521.
36. JAMES, R. W.; LEVIEV, I.; RUIZ, J.; PASSA, P.; FROGUEL, P. and GARIN, M. C. (2000): Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes. 49: 1390-1393.
37. FORTUNATO, G.; RUBBA, P.; PANICO, S.; TRONO, D.; TINTO, N.; MAZZACCARA, C; DE MICHELE, M.; IANUZZI, A.; VITALE, D. F.; SALVATORE, F. and SACHETTI, L. (2003): A paraoxonase gene polymorphism, PON1 (55), as an independent risk factor for increased carotid intima-media thickness in middle-aged women. Atherosclerosis. 167: 141-148.
38. MACKNESS, B.; MACKNESS, M. I.; ARROL, S.; TURKIE, W. and DURRINGTON, P. N. (1997): Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br. J. Pharmacol. 122: 265-268.
39. NUS, M.; FRANCES, F.; SÁNCHEZ- MONTERO, J. M.; CORELLA, D. and SÁNCHEZ- MUNIZ, F. J. (2006): Arylesterase activity and HDL-cholesterol levels are dependent on the PON55M and PON192R polymorphisms. International Symposium on Atherosclerosis. Roma (Comunicación oral publicada en Atherosclerosis Suppl 2006; 7: 333).
40. ECKERSON, H. W.; ROMSON, J.; WYTE, C. and LA DU, B. N. (1983): The human serum paraoxonase/arylesterase polymorphism. Am. J. Human Genet. 35: 214-227.
41. NUS, M.; SÁNCHEZ-MUNIZ, F. J. and SÁNCHEZ-MONTERO, J. M. (2006): A new method for the determination of arylesterase activity in human serum using Simulated Body Fluid. Atherosclerosis. 188: 155-159.